Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 22 Feb 2022 |
| Genmab Publishes 2021 Annual Report | 16 Feb 2022 |
| Genmab Files Annual Report with the U.S. Securities and Exchange Commission | 16 Feb 2022 |
| Genmab A/S has published its Articles of Association | 3 Feb 2022 |
| Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons | 26 Jan 2022 |
| Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2021 | 25 Jan 2022 |